Gyre Therapeutics' Hydronidone Cleared for Conditional Approval Pathway, Priority Review in China
Summary
Gyre Therapeutics announced that China's CDE agreed to a conditional approval pathway and priority review eligibility for its anti-fibrotic therapy, Hydronidone, based on positive Phase 3 data, with an NDA submission planned for H1 2026.
Key Events
-
CDE Alignment on Conditional Approval
China's Center for Drug Evaluation (CDE) agreed that existing Phase 3 clinical data for Hydronidone generally support a conditional approval New Drug Application (NDA) for CHB-associated liver fibrosis.
-
Priority Review Eligibility Confirmed
The CDE indicated that Hydronidone meets the criteria for inclusion in China's Priority Review and Approval Program for Innovative Drugs, subject to formal filing and review.
-
NDA Submission Planned for H1 2026
Gyre Pharmaceuticals plans to submit the conditional approval NDA for Hydronidone in the first half of 2026.
-
Confirmatory Clinical Trial Planned
An additional confirmatory Phase 3c clinical trial will be conducted to support potential conversion from conditional to regular approval.
Analysis
This 8-K filing signals a significant regulatory advancement for Gyre Therapeutics' lead anti-fibrotic drug, Hydronidone, in the substantial Chinese market. The consensus reached with China's CDE for a conditional approval pathway and eligibility for priority review substantially de-risks the drug's path to commercialization. This development, building on previously reported positive Phase 3 results and Breakthrough Therapy Designation, positions Hydronidone to address a large unmet medical need in chronic hepatitis B-associated liver fibrosis. Investors should monitor the upcoming NDA submission in the first half of 2026 and the progress of the confirmatory clinical trial for full approval.
At the time of this filing, GYRE was trading at $7.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $619M. The 52-week trading range was $6.11 to $13.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.